Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Takeda
Biotech
Roivant’s midstage asset fails to show benefit in lung disease
Given the results, Kinevant is terminating development of the candidate—dubbed namilumab—as a potential sarcoidosis treatment.
Gabrielle Masson
Dec 3, 2024 10:32am
Takeda pays Keros $200M upfront for rival to BMS' Reblozyl
Dec 3, 2024 7:30am
Takeda stops phase 2 post-anesthesia trial over slow enrollment
Oct 31, 2024 5:29am
Ironwood makes further bid for $1B GI drug with subgroup data
Oct 28, 2024 12:33pm
Takeda axes Huntington’s pact, freeing Wave to pursue partners
Oct 16, 2024 8:07am
Biopharma layoff rate stabilizes in Q3: Fierce Biotech analysis
Oct 4, 2024 3:50pm
